Dissertations / Theses on the topic 'Hepatitis B Victoria Prevention'

Master of Dental Surgery
This work was digitised and made available on open access by the University of Sydney, Faculty of Dentistry and Sydney eScholarship . It may only be used for the purposes of research and study. Where possible, the Faculty will try to notify the author of this work. If you have any inquiries or issues regarding this work being made available please contact the Sydney eScholarship Repository Coordinator - ses@library.usyd.edu.au

Thesis (MPH))University of Limpopo (Medunsa Campus), 2011.
Introduction: Hepatitis B virus (HBV) is a highly infectious virus responsible for considerable morbidity and mortality world wide. Chronic HBV carriers can transmit HBV parenterally in a hospital setting putting healthcare workers (HCWs) and their patients at risk of infection. Aim and objectives: This study aimed to investigate knowledge, attitudes and practices towards prevention and control of HBV amongst nurses, doctors and laboratory personnel. Objectives were to determine: (a) the knowledge; (b) the attitudes; (c) the practices of nurses, doctors and laboratory personnel; (d) if there are any associations between (1) knowledge and practice, and (2) attitudes and practice; (e) the predictors of HBV vaccination uptake. Materials and Methods: This was a cross-sectional descriptive study. Self-administered questionnaires were distributed to doctors, laboratory staff and nurses at Princess Marina Hospital. Results: Two hundred questionnaires were distributed and a total of 117 were returned, giving an overall response rate of 58.5%. More doctors had good knowledge (38.9% [7/18]), followed by 20% (4/20) of laboratory staff and 11.4% (9/79) of nurses. Most staff (100% [20/20] of laboratory staff; 97.5% [77/79] of nurses; 94.4% [17/18] of doctors) had positive attitudes. More laboratory staff (100 [20/20]) displayed good practices, followed by nurses (94.9% [75/79]); and lastly doctors (88.9% [16/18]). There were no significant associations between knowledge or attitudes and practices. Vaccination was inadequate, with 50.9% (59/116) of HCWs having received at least one dose, and of these only 61% (36/59) receiving all 3 doses. Needle stick injuries occurred in 31.6% (37/117), while 33.9% (39/115) reported blood or body fluid splashes. None of the HCWs accessed PEP after exposure. Being a laboratory worker (OR: 148.4) or doctor (OR: 125.7) were the only predictors of vaccination uptake. Conclusion: There is need to increase knowledge of HCWs, vaccination availability, vaccination uptake, PEP, and reduce the exposures of HCWs.

Introduction: Hepatitis B is a highly contagious infection. Basic knowledge about hepatitis B is necessary; with more knowledge people take preventive actions against hepatitis B, such as using stick proof cannulas. In Thailand an expected number of 8-20% of the population are currently carriers of the HBV infection.   Aim: The aim of the study was to investigate the knowledge about hepatitis B and the attitudes towards the vaccination among Thai university students.   Method: A cross-sectional study with a quantitative method was used. 280 students participated in the study, and the response rate was 93.9 %. The data was analysed using SPSS Statistics 20.   Result: Both genders had poor knowledge about hepatitis B, however 91.1 % of the students had heard about hepatitis B. About half of the students (55.4 %) knew correctly that hepatitis B is sexually transmitted and 40.0 % of the students knew that hepatitis B could cause liver cancer. There was no significant difference in knowledge between the genders. The attitudes towards the vaccine were satisfactory between both genders, 89.3 % of the students knew that healthy people need the vaccination and 81.1 % believed that they would receive the vaccination. However, only 43.6 % knew that the vaccination could be free or low cost through certain programs. There was a significant difference (p-value = 0.042) between the genders; the male students had a more positive attitude towards the vaccine than the female students.   Conclusion: The results from the Thai students showed that more information about the Hepatitis infection is needed to raise awareness among this certain group of people. Information about how it is transmitted is essential to improve the public health. It is also important to improve the individual's self-care, to encourage them to receive the vaccination. From a nursing point of view improving the knowledge about HBV and a positive attitude towards the vaccine in the prolonging contribute to improve the public health by getting a lower rate of cases with HBV.

Thesis (MPH)--University of Limpopo, 2010.
Introduction: Hepatitis B infection is a serious blood-borne disease caused by the hepatitis B virus (HBV) which attacks the liver, and is the leading cause of liver cancer and cirrhosis of the liver. HBV can be transmitted through exposure to infected blood and human secretions through needle stick / sharps injuries and splashes. Thus nurses are at high risk for HBV infection. The aim of the study: To investigate the knowledge, attitudes and practices (KAP) regarding the prevention of hepatitis B virus infections, in final year college student nurses in Gauteng province. Methods: A cross-sectional quantitative survey on 350 final year nursing students was conducted in three Gauteng province nursing colleges, using an anonymous self administered questionnaire with questions on knowledge, attitudes, and practices regarding HBV. The data were analysed using SPSS (statistical package for social science studies). Results: Of 350 questionnaires distributed, 312 student nurses returned completed forms (response rate: 89.14% [312/350]). The majority were females (86.8% [270/331]) and were below 31 years of age (30.1% [93/309]). The majority (87.6% [271/310]) had good knowledge of the causes and prevention of HBV. The unvaccinated respondents had fairly low positive attitudes, with a mean, mode and median score of 1 (possible score from -4 to +4). The majority (79% [244/310]) practiced good compliance with universal precautions of, and the majority (64.9% [202/311]) were vaccinated. College A displayed significantly higher knowledge (p<0.001), positive attitudes (p=0.001) and safer practices (p<0.001) than college B and C.

Thesis (D Phil. (Medical Virology))--2008.
Background and Objectives: South Africa is one of the countries highly affected by human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Some drugs (e.g. lamivudine) used as part of combination antiretroviral regimens for HIV treatment have dual activity against HBV and HIV. Despite high infection rate with both viruses, routine screening for HBV before initiation of treatment for HIV is not yet a standard practice. This study undertook to investigate: (1) the burden of HBV co-infection in HIV-positive patients enrolling for highly active antiretroviral therapy (HAART) at Dr George Mukhari hospital, (2) the impact of anti-HBV containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, (3) the co-evolution of HBV and HIV drug-resistant strains, and (4) the correlation of HBV genotypes with response to anti-HBV containing HAART regimens. Study Population and Methods: To investigate the burden of HBV/HIV co-infections, a cohort of 192 HIV patients who were candidates for ARV treatment at Dr George Mukhari hospital were studied by screening for HBV serological markers (HBsAg, anti-HBs and anti- HBc) (Elecsys 2010, Roche Diagnostics) and HBV DNA with an in-house nested PCR assay targeting HBV polymerase gene. Quantitation of HBV DNA positive samples was performed with Roche Cobas Taqman HBV test 48 assay. To investigate the impact of lamivudine-containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, as well as the coevolution of HBV and HIV drug-resistant strains, a total of 78 patients were studied. HBV virological response against lamivudine containing-HAART regimens [1a (lamivudine, stavudine and efaverenz); 1b (lamivudine, stavudine and neviripine)] was measured (Cobas Taqman HBV test 48, Roche diagnostics). HBV direct sequencing targeting HBV polymerase gene was performed on all baseline samples (n=78) and additional samples collected at various time points (n = 45). Direct sequencing was also performed on 30 HIV baseline samples targeting the HIV reverse transcriptase and protease genes (Spectru-Medix SCE 2410 Genetic Analysis System and ABI PRISM® 3100 Genetic Analyzer version 3.7). To explore the genetic diversity of HBV and HIV strains circulating in Pretoria and surrounding areas, as well as the correlation of HBV genotypes with response to lamivudine-containing-HAART regimens in co-infected patients, all baseline and follow-up HBV and HIV sequences were analysed, compared and correlated with treatment. Sequence alignments and phylogenetic studies for both HBV and vi HIV were conducted with MAFFT, Mega 4 and neighbour joining phylogenetic trees generated with the PHYLIP programme. Results: Three significant findings were observed in this study. Firstly, the majority of South African HIV patients enrolling for HAART were exposed to HBV infection and either had acute or chronic HBV infections. A total of 63.0% of patients were found to have one or more HBV markers, with 40.6% having detectable HBV DNA as an indication of replication. The study also detected 22.9% with positive HBsAg, and 23% of 77% HBsAg-negative patients having occult hepatitis B infection. Secondly, HBV/HIV co-infected patients do benefit during the management of HIV infections with lamivudine-containing HAART regimens. A total of 68.4% of patients responded to HAART, with undetectable HBV DNA during 18 to 24 months of follow-up. A total of 91.3% of HIV patients also responded to HAART with an undetectable HIV viral load during 6 to 12 months of follow-up. However, a total of 18% of patients had persistent HBV DNA, yielding various HBV virological responses against lamivudine containing-HAART regimens. This proportion of patients poses a question regarding the management of HBV and HIV coinfections, as guidelines on the use of HAART with anti-HBV activity from developed countries, may not necessarily be followed in developing countries. The results further showed that baseline drug-resistance was more frequent with HIV than HBV in this cohort of patients. The following HIV primary drug resistant mutants were observed: nine major NRT's primary mutants, M41L (1/30), E44A (1/30), V75M (1/30), F77L (1/30), V118I (1/30), M184V (1/30), L210S (1/30), T215Y (1/30) and V90I (1/30), and five major NNRT’s primary mutants were also detected, K103N (3/30), Y318CFSY (1/30), E138Q (1/30), P225H (1/30) and K238T. However, all followup samples had undetectable HIV viral load. In contrast to HIV, only one patient was detected with HBV mutant, M204I, at baseline. The mutant reversed to wild type during 6 months and other follow-up (12, 18 and 24 months). Finally, this study indicated that the HBV genotype A is still the most prevalent genotype circulating in South Africa. Of the 78 HBV sequences, 77 were genotype A and 1 sequence was genotype G. This is the first report from Africa of the detection of HBV genotype G. HIV subtype C remains the predominant prevailing subtype in South Africa. HBV genotype or HIV subtype C was not observed to influence any treatment outcome following treatment with vii lamivudine-containing HAART regimens. The study also indicated that patients on lamivudinecontaining HAART regimens do benefit not only by suppressing HIV and HBV viral load, but also improving immunity (i.e. CD4 cells count increases). Conclusion: Overall, the present study highlights the need for screening HBV before initiation of any HAART containing anti-HBV regimens in HBV/HIV co-infected patients. It necessitates the use of molecular assays for effective laboratory in diagnosis of occult HBV infections in HIVpositive patients, especially in developing countries where these assays are not widely available. While lamivudine-containing HAART regimens do benefit both HBV and HIV patients in co-infected individuals, however, whether HBV virological response is temporary or sustained is unknown at this stage. What is certain is that these patients require an effective monitoring programme as (1) a small percentage experience variable HBV virological responses (partial, reactivation, or no response), and (2) hepatitic flares are likely to develop if HAART is terminated (e.g. by patient), or the current HAART regimen is switched to another regimen without anti-HBV activity. HBV genotype A remains the dominant genotype in South Africa, but novel genotypes can be detected. HIV subtype C was found to be the prevalent subtype. HBV genotype or HIV subtype C were not seen to influence any treatment outcome following treatment with lamivudine-containing HAART regimens. Recommendations: HIV patients should be screened for HBV before initiation of anti-HBV containing HAART regimens. The screening of HBV in HIV patients is also important since some drugs included as part of HAART (e.g. nevirapine) may cause hepatotoxicity and exacerbate HBV infections leading to increased morbidity and mortality due to liver complications. Immunization and immune boosters of HIV patients with low (< 10IU/L) or no immunity against HBV should be done as this could be beneficial, although these patients may not respond optimally, or their immunity may wane faster due to immunocompromised status. Monitoring of both HBV and HIV resistant strains should be conducted for timely detection for the occurrence of multiple resistant mutations, which could limit future therapeutic option for both viruses.

Вірусні гепатити з контактним механізмом передачі в Україні за ступенем негативного впливу на здоров’я населення займають домінуюче місце у структурі інфекційної патології. Актуальність вірусного гепатиту В (ВГВ) зумовлена високим рівнем захворюваності, складністю патогенезу, недостатньою ефективністю лікування, важкими ускладненнями та наслідками хвороби. Хронізація ВГВ спостерігається в середньому у 5-15 % випадків, у частини хворих можливий подальший розвиток цирозу та раку печінки. За даними ВООЗ, у світі на хронічний ВГВ страждає понад 350 мільйонів осіб.

Made available in DSpace on 2014-07-29T15:04:35Z (GMT). No. of bitstreams: 1 Grecia Carolina Pessoni.pdf: 1074052 bytes, checksum: 1a6c39b31bb8fa1188db36c9d804d866 (MD5) Previous issue date: 2010-04-05
In order to investigate the seroepidemiological profile of hepatitis B virus (HBV) infection among female inmates from the Metropolitan Region of Goiânia, 148 women were interviewed on sociodemographic and risk factors for HBV. After, blood samples were collected for the detection of HBsAg, anti-HBs and anti-HBc by enzyme linked immunosorbent assay (ELISA). The majority of women had less than 36 years of age (77.1%), less than nine years of education (69.8%) and family income less than two Brazilian minimum wage (65.2%). Almost half (46.6%) of female inmates reported stable relationships. An overall HBV prevalence of 18.9% was found. One (0.7%) woman was HBsAg-positive. The anti-HBc was detected in 27 (18.2%) women, being 25/27 associated to anti-HBs, and 2/27 alone. In only 36 (24.3%) female inmates the anti-HBs isolated was detected, suggesting previous hepatitis B vaccination. The analysis of risk factors showed that age over 35 years, less than ten years of education, sexual partner in the prison , and previous STD were independently associated to HBV markers. The results of this study highlight the need for action to prevent the hepatitis B in the prison environment, including health education and immunization against hepatitis B.
Com o objetivo de investigar o perfil soroepidemiológico da infecção pelo vírus da hepatite B (HBV) em reeducandas da Regional Metropolitana de Goiás, 148 mulheres foram entrevistadas sobre dados sócio-demográficos e fatores de risco para a infecção pelo HBV. A seguir, foram coletadas amostras sanguíneas para a detecção dos marcadores HBsAg, anti-HBs e anti-HBc pelo ensaio imunoenzimático (ELISA). A maioria possuía menos de 36 anos de idade (77,1%), tempo de estudo inferior a nove anos (69,8%) e renda familiar de até um salário mínimo (65,2%). Praticamente a metade (46,6%) referiu relacionamento estável. Do total de reeducandas, verificou-se uma prevalência global de 18,9% para os marcadores da infecção pelo HBV. Uma (0,7%) reeducanda apresentou positividade para o HBsAg. O marcador anti-HBc foi detectado em 27(18,2%) mulheres, sendo que em 2/27 isoladamente e, em 25/27 associado ao anti-HBs. Em somente 36 (24,3%) reeducandas detectou-se positividade isolada para o anticorpo anti-HBs, sugerindo vacinação prévia contra o vírus da hepatite B. A análise dos fatores de risco mostrou que idade acima de 35 anos; escolaridade inferior a 10 anos, parceiro na agência prisional e antecedentes de DST foram independentemente associados aos marcadores de exposição ao HBV. Os resultados deste estudo evidenciam a necessidade de ações de prevenção da hepatite B no ambiente carcerário, incluindo educação em saúde e vacinação contra hepatite B.

M.Tech. (Homoeopathy)
According to the World Health Organisation (2008), an estimated two billion individuals globally, are infected with Hepatitis B (HBV). South Africa reported 864 notified new cases between 2001 and 2004 (Department Of Health, 2005), with an estimated 3-4 million chronic HBV infected black South Africans (Kew, 2008). Kwa-Zulu Natal and Free State were the most affected provinces; while 20-39 years was the most affected age group as of 2005 (Department Of Health, 2005). Workers in the health industry, intravenous drug users and children of women who have Hepatitis B are at the most risk for contracting this disease from blood products and body fluids (Immunization Action Coalition, 2007; Boon et al., 2006), where contraction of the disease can lead to liver cirrhosis, fibrosis and hepato-cellular carcinoma (Highleyman, 2008). The Expanded Program on Immunization (EPI) of the South African Department of Health (2009) suggests vaccination for Hepatitis B should be administered at six, ten and fourteen weeks, or a dose every month for 3 months. Adverse reactions associated with the vaccine include “Guillain-Barre Syndrome, arthritis, demyelinating nervous system disease” (Pratt, 2008) and anaphylaxis (Danis & Halm, 1997). Alternatives that may assist in avoiding such symptoms include: waiting until adolescence to vaccinate (Slonim et al., 2005); only vaccinating high risk groups (Francois et al., 2002); or researching an alternative (Romm, 2001). Homeoprophylaxis is the use of homeopathy to prevent the contraction or development of disease (Zoltan, 2000) and its successful use has been recorded in various disease types and locations. There have been very few studies to show the effect of individual homeopathic nosodes used as prophylactic treatment in their related diseases, with almost none of these utilising any means of serological testing (Bevan-Jones, 2009; Frost et al., 2003; Sheffield, 2006). The aim of this study was to determine the production of the antibody to the surface antigen of Hepatitis B (anti-Hbs) due to Hepatitis B 12cH nosode administration.   Forty-three participants ranging, in ages 18 to 65 years, who tested negative for the presence of anti-HBs, took part in this four week long, double-blind, placebo controlled study. Participants were randomly placed into either the Verum or Placebo group, each group receiving four lactose powders to be taken weekly for four weeks. The Active group received lactose powders medicated with Hepatitis B 12cH, whereas the Placebo group received lactose powders medicated with 96% alcohol. Participants underwent a repeat of the serum/plasma antibody testing at the conclusion of the study to determine if there were anti-HBs present in their blood. The results were then statistically analysed using nonparametric testing: Chi-squared independent test, Mann-Whitney test and Sign test. These showed that there was no change measurable effect on the surface antigen of hepatitis B (anti-HBs) of either the Verum (active medication) or Placebo group. Primary preventative medicine is becoming increasingly popular (Kuehlein et al., 2010). Both vaccination and homeoprophylaxis are examples of primary preventative medicine, where the aim is to prevent future disease. Vaccinations encourage the production of antibodies via the activation of T-helper cells and B-lymphocytes, thus providing a template for immunity against future infections (Miller, 2000; Janeway et al., 2001). While the mechanisms of vaccination are well understood, those of homeoprophylaxis are still being investigated. One theory is that nosodes enable the body to overcome diseases. Several studies have been conducted on the effects of nosodes (Bracho et al., Prophylactic vaccination against human papilloma virus infection and disease in women: a systemic review of randomized control trial.; Gosavi et al., 2012; Shuller, 2010) and have shown favourable results in the prevention of diseases associated with those homeopathic nosodes. However, only two studies have investigated the effects that nosodes have on the antibodies of the immune system (Hoover, 2006; Neustaedter, 2002) showing the need for further studies conducted in this area. The study showed that homeopathically prepared Hepatitis B 12cH nosode is not capable of eliciting an immune response that would result in the production of the antibody to the surface antigen of Hepatitis B, and thus not able to provide immunity against Hepatitis B.

Hepatitis B virus (HBV) is hyperendemic to southern Africa and parts of Asia where it is a major cause of serious liver disease. Licensed antivirals for chronically infected individuals are only partially effective and approximately one million deaths occur annually as a result ofpersistent infection with the virus. Although RNA interference (RNAi) based gene silencingof HBV has been successfully demonstrated, difficulties with delivery of anti-HBV RNAieffectors remains an obstacle to their clinical use. Recombinant adenoviruses (Ads), amongst the most efficient hepatotropic gene vectors following systemic administration, have been successfully used to deliver expressed anti-HBV RNAi sequences. However, a drawback of Ad vectors is diminished efficacy and toxicity that results from stimulation of innate andadaptive immunity.To attenuate these effects we used polyethylene glycol (PEG) to modify first generation recombinant Ad (FG Ad) vectors that express an anti-HBV short hairpin (shRNA) sequence. Efficient hepatocyte transduction occurred and expressed shRNAs were processed to generate intended HBV-targeting guides. Inhibition of HBV replication was achieved after intravenous administration of PEGylated or native recombinant first generation Ads (FG Ads) to HBV transgenic mice. Circulating HBV viral particle equivalents (VPEs) remained low for 3 weeks and began to increase after 5 weeks. A second dose of PEGylated anti-HBV Ad caused a less sustained decrease in circulating VPEs, but no silencing after a second dose was observed in animals treated with unmodified vector. Release of inflammatory cytokines was elevated in animals receiving unmodified vectors and only a modest increase in monocyte chemotactic protein-1 (MCP-1) was observed in mice that received a second dose of PEG Abstract Ads. Also, polymer-conjugated vectors induced a weaker adaptive immune response and were less hepatotoxic than their unmodified counterparts. To address concerns about the transient nature of transgene expression by FG Ads resulting from immunostimulation, third generation helper-dependent (HD Ad) were utilised to delivered anti-HBV RNAi effectors. Seven days after intravenous administration of infectious HD Ads to HBV transgenic mice, 80-90% of hepatocytes were transduced and markers of HBV replication were decreased by approximately 95% which was sustained for 8 weeks. HD Ad-induced release of proinflammatory cytokines was minimal in preparations that were enriched with infectious particles. PEGylated HD Ad vectors caused similar anti- HBV effects and may be useful to evade interaction with vector-sequestrating receptors and further attenuate immunostimulation. Collectively these observations indicate that PEG modification of Ads and the use of HD Ads may have utility for delivery of therapeutic HBVsilencing sequences. Future work will focus on improving strategies to avoid immune detection and utilisation of HD Ad vectors for other HBV targeting sequences.

Hepatitis B virus (HBV) is a major global public health burden, with over 350 million people chronically infected. This results in approximately 600,000 liver cancer-related deaths annually. Chronic HBV infections are normally managed with long-term anti-HBV therapeutics, such as reverse transcription inhibitors, which target post-transcriptional viral processes without affecting the cccDNA. Treatment failure however is largely as a result of the stability of this episomal viral DNA. The cccDNA minichromosome serves as a reservoir of HBV DNA and is capable of re-establishing viral replication following withdrawal of treatment. Designer nucleases, like transcription activator-like effector nucleases (TALENs), have recently been used to create double stranded breaks (DSBs) at target-specific endogenous DNA loci. These nucleases are designed as pairs, which upon dimerisation cleave double-stranded DNA. Subsequent activation of the cellular non-homologous end-joining (NHEJ) pathway often results in targeted mutagenesis at the DSB site. As TALENs may be designed to bind to any DNA sequence, they are commonly used as genetic engineering agents. Inactivation of HBV cccDNA, using these engineered TALENs, presents a unique approach to disabling viral replication permanently. To investigate this, a panel of TALENs targeting the core (C), surface (S) and two different polymerase (P1 and P2) regions of HBV cccDNA were generated using a Golden gate modular assembly approach. TALENs were initially tested in two liver-derived cell lines. Firstly as transient co-transfections in Huh7 cells using a HBV replication competent plasmid, followed by long term investigations in HepG2.2.15 cells which model HBV replication in vitro. Inactivation of HBV was determined by measuring markers of viral replication, whilst TALEN-mediated targeted disruption was verified by T7 endonuclease 1 (T7E1) or CELI endonuclease assays and sequencing. In vitro, the S TALEN inhibited HBsAg secretion by 80% in Huh7 cells and 60% in HepG2.2.15 cells. Furthermore, S TALEN-mediated targeted disruption occurred in 35-47% of cccDNA copies, whilst the C TALEN resulted in 11% targeted disruption of cccDNA in without inhibition of HBsAg expression. The P2 TALEN showed no anti-HBV efficacy, however the P1 TALEN inhibited HBsAg expression by up to 60% without any evidence of site-directed cleavage. As this TALEN binding site spans the HBV Enhancer I sequence, knock-down of HBsAg expression is most likely to occur as a result of transient transcriptional repression. To confirm whether permanent repression of HBV transcription could be achieved, a KRAB-based transcription activator-like repressor (rTALE) targeting the HBV pre-S2 promoter was generated. Using an in vitro reporter gene assay, the pre-S2 rTALE inhibited luciferase expression by up to 90%. However this was only achieved using high molar concentrations of the repressor, suggesting multiple rTALEs may improve HBV transcriptional repression. As the S and C TALENs displayed significant anti-HBV efficiency in vitro, they were tested in a murine hydrodynamic injection model of HBV replication. In vivo, the S TALEN inhibited HBsAg secretion by 95% and induced disruption in 77–87% of HBV DNA targets. In addition the C TALEN inhibited HBcAg expression and induced disruption in 78-93% of HBV DNA targets. Additionally, serological analysis showed a reduction in circulating virions and no apparent liver toxicity, as determined by real-time PCR (qPCR) and aspartate transaminase (AST)/ alanine aminotransferase (ALT) liver function tests respectively. Deep sequencing at the S and C TALEN binding sites showed targeted mutagenesis of HBV DNA in samples extracted from murine hepatocytes transfected with TALENs, however wild-type sequences were exclusively detected in mice that had not been treated with anti-HBV TALENs. Furthermore, frameshift deletions were predominantly detected indicating major disruptions in the HBV surface and core sequences. These results indicate that TALENs designed to disable and silence HBV cccDNA are effective both in vitro and in vivo and as such provide a promising therapeutic approach to treat this serious infection.

碩士
義守大學
管理學院管理碩士在職專班
100
Infected with hepatitis B virus carriers is one of the main cause liver cancer death, emotional negative message strategies most commonly used in social marketing of fear appeals (fear appeal), and explained from the perspective of the fear level of motivation and repeat the message, when the viewer how to have a negative emotional correlation analysis of the cognitive approach to obtain detailed information, its purpose is to eliminate or improve the source of negative emotions. For the structure of the regulatory focus theory to explore the different fears, with a different promotion regulatory focus and adjust the focus on advertising effectiveness and impact of prevention, and we understand the motivation of the study of preventive health care for the hepatitis B From the study results, the best idea in the low fear of duplicate message acceptance. Repeat the message in the high fear, the concept of the first message received significantly better than the second.

碩士
美和科技大學
護理系健康照護碩士班
107
Background: Vietnam has a high prevalence of hepatitis B; an estimated 8.6 million people are infected with the hepatitis B virus. The prevalence of chronic hepatitis B infection is estimated at 8.8% in women and 12.3% in men. Nurses doing regular care contact with blood and blood products of patients should be very easily infected with the hepatitis B virus. In particular, nurses in Thu Duc district hospital work in very difficult conditions, work pressure is a contributing factor to increase the rate of infection and poor awareness in preventing blood-borne diseases. Do not strictly compliance while doing work has contact with blood and blood products. Therefore,more than anyone else, most health care workers are direct caregivers who need to have the knowledge, attitude and practice to strictly adhere to the prescribed measures and procedures when exposuring to the patient's specimens, especially patients with HBsAg (+), first protects them and then protects the community from infection. Objective: The overall purpose of the study was to explore the knowledge, attitude,practices of nurses and the relative factors on prevention of hepatitis B. Methods: This is a cross-sectional study and 206 nurses of Thu Duc district hospital in Vietnam were interviewed with structured questionnaires. Questionnaires included demographic characteristics, knowledge, attitude, practices of nurses on prevention hepatitis B. Independent sample, T-test, ANOVA, Pearson‘s correlation, and regression model were used to analyze data. Results: (1) The proportion of nurses with proper knowledge about hepatitis B prevention is generally high (74.3%), the positive attitude of nursing care about hepatitis B is relatively low (44.2%), proportion of proper nursing practices for prevention of hepatitis B is moderate (50%). (2) Departments (F = 5,079, p <0.01) and educational level (F = 5,591, p <0.01) are associated with knowledge of hepatitis B prevention of nurses; Gender (t = 2,202, p <0.05), departments (F = 6.117, p <0.001)and educational level (F = 5,987, p <0.01) are related to attitude of hepatitis B prevention of nurses; Age (F=3.139, p <0.05), and educational level (F=2.691, p<0.05) are associated with practices of hepatitis B prevention of nurses. (3) Nursing knowledge, attitude and practices about preventing hepatitis B were positively correlated and statistically significant. (4) Attitudes and knowledge predict 14.4% of the variance in practices on preventing hepatitis B of nurses. Conclusion: Nurse's knowledge, attitude and practices is an important factor on preventing hepatitis B. The findings from this study have provided the foundation for education to enable nurse to improve their knowledge, attitude and practices on preventing hepatitis B.

The study investigated knowledge, attitudes and vaccination status of registered nurses regarding prevention and control of hepatitis B (HB). An analytical, cross-sectional study was conducted, and data was collected using self-administered questionnaires. 53.0% of the respondents (n=219) had good knowledge and 96.3% had positive attitudes regarding HB prevention and control. 86.8% had received at least 1 dose of the HB vaccine, but only 54.7% had received the 3 doses for complete vaccination. A positive attitude score was a significant predictor of HB vaccination uptake (OR=1.424, p=0.003). Female registered nurses were 3.479 times (95% CI: 1.495-8.098; p=0.004) more likely to be vaccinated than male registered nurses. Registered nurses are aware that hepatitis B virus infection can be prevented by a safe and effective vaccine, however, there is need to improve awareness and encourage complete HB vaccination uptake among all registered nurses to ensure their protection against the risk of HBV infection.
Health Studies
M. P. H. (Health Studies)